Where the manual cost in claim adjudication actually sits
The line-item every health insurance COO reads on a Monday morning. Reviewer hours per case, the appeal-rate tax, the documentation-shortfall denials. What gets cheaper, and what doesn't, when AI handles the front pass.
If you run operations at a mid-sized Indian health insurer, the largest line item that doesn’t involve actually paying claims is the team that decides whether to pay them. The economics of claim adjudication are worth understanding because they explain why this is the wedge with the cleanest ROI for AI — and also why the savings story is more complicated than the vendor decks suggest.
Where the manual cost actually sits
Adjudication cost decomposes into four buckets:
- Reviewer hours per case. Salaried nurse reviewers, plus team-lead oversight, plus medical-officer review on flagged cases. This is the headline number that AI pitches always lead with.
- Documentation-shortfall denials. Cases denied not because they should be denied, but because the documentation didn’t arrive complete. These come back as appeals.
- The appeal-rate tax. Every appealed case is reviewed again — sometimes twice. The cost of an appeal is several multiples of the cost of the original decision.
- Operational drag. SLAs missed because the team can’t scale fast enough during seasonal surges. Hospital partnerships strained because cashless approvals are slow.
What AI changes — and what it doesn’t
AI-driven adjudication takes a meaningful share of the reviewer-hours bucket. That much is obvious. What’s less obvious is what happens to the other three buckets.
Documentation-shortfall denials go down. The agent is faster and more thorough at identifying what’s missing in an incomplete claim than a human reviewer working through a queue. The recommendation comes back as “refer for documentation request” rather than “deny”, and the customer experience improves.
The appeal rate drops. Decisions that cite their grounding in the policy text are harder to challenge successfully. The cases that should be appealed still are; the cases that were appealed only because the rationale was opaque stop being appealed.
Operational drag attenuates. Seasonal surges become a quota-pricing problem with the foundation-model provider, not a hiring problem.
The boring win isn’t reviewer-headcount reduction. It’s the appeal-rate compression that follows from citation-backed decisions.
What doesn’t change
Three things stay the same:
- Cases that should be denied are still denied. The agent doesn’t approve borderline cases to be nice. The confidence-floor primitive means borderline cases route to a human; the medical-officer decision is the one that counts.
- The medical-director sign-off load doesn’t go away. It just moves up the value chain. The medical director spends less time on routine approvals and more time on policy calibration and edge-case review — which is where their training pays off.
- Regulator engagement doesn’t disappear. IRDAI still asks questions. The difference is the answer takes minutes to assemble, not weeks.
The honest framing for a CFO
If you build the ROI case as ‘reduced reviewer headcount’, the deal looks attractive but exposes you to backlash. If you build it as ‘reviewer team redirected to medical-officer review, appeal-rate compression, faster cashless turnaround’, the deal looks less spectacular per line item but the total impact is larger and the deployment risk is lower. The reviewer team you keep is the team that calibrates the system; the reviewer team you let go is the team you lose institutional knowledge with.
First pilots in health insurance work best when the goal is operating-model improvement rather than headcount reduction. The headcount conversation comes after the eval set has been signed off by the medical director and the first quarter of shadow traffic has been benched.